Fatty acid metabolism in carriers of apolipoprotein e epsilon 4 allele: Is it contributing to higher risk of cognitive decline and coronary heart disease?

Nutrients

Volumn 6, Issue 10, 2014, Pages 4452-4471

  Chouinard Watkins, Raphaël ^a   Plourde, Mélanie ^a  

^a UNIVERSITY INSTITUTE OF GERIATRICS OF SHERBROOKE   (Canada)

Author keywords

Apolipoprotein E epsilon 4 allele; Cognitive decline; Coronary heart disease; Docosahexaenoic acid; Fatty acids

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; ARACHIDONIC ACID; C REACTIVE PROTEIN; DOCOSAHEXAENOIC ACID; FATTY ACID BINDING PROTEIN; HIGH DENSITY LIPOPROTEIN; LINOLENIC ACID; LONG CHAIN FATTY ACID; LONG CHAIN OMEGA 3 FATTY ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; OMEGA 3 FATTY ACID;

ADIPOSE TISSUE; ALLELE; ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BODY MASS; COGNITION; DIET SUPPLEMENTATION; DIETARY INTAKE; FATTY ACID METABOLISM; FATTY ACID OXIDATION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HETEROZYGOTE; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIPID HOMEOSTASIS; MEMBRANE PERMEABILITY; META ANALYSIS (TOPIC); NONHUMAN; PEROXISOME; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; COGNITIVE DEFECT; CORONARY ARTERY DISEASE; DRUG EFFECTS; FISH; GENETIC PREDISPOSITION; GENETICS; HOMEOSTASIS; LIPID METABOLISM; METABOLISM; OXIDATION REDUCTION REACTION; RISK FACTOR;

ALLELES; ALZHEIMER DISEASE; ANIMALS; APOLIPOPROTEIN E4; COGNITION DISORDERS; CORONARY DISEASE; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; FISHES; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HOMEOSTASIS; HUMANS; LIPID METABOLISM; OXIDATION-REDUCTION; RISK FACTORS;

EID: 84908221510     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu6104452     Document Type: Review

References (134)

1. Weisgraber, K.H.; Rall, S.C., Jr.; Mahley, R.W. Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the Apo-E isoforms. J. Biol. Chem. 1981, 256, 9077-9083.
2. Garenc, C.; Aubert, S.; Laroche, J.; Girouard, J.; Vohl, M.C.; Bergeron, J.; Rousseau, F.; Julien, P. Population prevalence of APOE, APOC3 and PPAR-alpha mutations associated to hypertriglyceridemia in French Canadians. J. Hum. Genet. 2004, 49, 691-700.
3. Bullido, M.J.; Artiga, M.J.; Recuero, M.; Sastre, I.; Garcia, M.A.; Aldudo, J.; Lendon, C.; Han, S.W.; Morris, J.C.; Frank, A.; et al. A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia. Nat. Genet. 1998, 18, 69-71.
4. Rall, S.C., Jr.; Weisgraber, K.H.; Mahley, R.W. Human apolipoprotein E. The complete amino acid sequence. J. Biol. Chem. 1982, 257, 4171-4178.
5. Mahley, R.W. Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science 1988, 240, 622-630.
6. Lin, C.T.; Xu, Y.F.; Wu, J.Y.; Chan, L. Immunoreactive apolipoprotein E is a widely distributed cellular protein. Immunohistochemical localization of apolipoprotein E in baboon tissues. J. Clin. Investig. 1986, 78, 947-958.
7. Elshourbagy, N.A.; Liao, W.S.; Mahley, R.W.; Taylor, J.M. Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets. Proc. Natl. Acad. Sci. USA 1985, 82, 203-207.
8. Liu, M.; Kuhel, D.G.; Shen, L.; Hui, D.Y.; Woods, S.C. Apolipoprotein E does not cross the blood-cerebrospinal fluid barrier, as revealed by an improved technique for sampling CSF from mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2012, 303, R903-R908.
9. Pitas, R.E.; Boyles, J.K.; Lee, S.H.; Foss, D.; Mahley, R.W. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim. Biophys. Acta 1987, 917, 148-161.
10. Farrer, L.A.P.; Cupples, L.A.P.; Haines, J.L.P.; Hyman, B.M.D.P.; Kukull, W.A.P.; Mayeux, R.M.D.; Myers, R.H.P.; Pericak-Vance, M.A.P.; Risch, N.P.; van Duijn, C.M.P. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: A meta-analysis. JAMA 1997, 278, 1349-1356.
11. Coon, K.D.; Myers, A.J.; Craig, D.W.; Webster, J.A.; Pearson, J.V.; Lince, D.H.; Zismann, V.L.; Beach, T.G.; Leung, D.; Bryden, L.; et al. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J. Clin. Psychiatry 2007, 68, 613-618.
12. Kok, E.; Haikonen, S.; Luoto, T.; Huhtala, H.; Goebeler, S.; Haapasalo, H.; Karhunen, P.J. Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann. Neurol. 2009, 65, 650-657.
13. Filippini, N.; Zarei, M.; Beckmann, C.F.; Galluzzi, S.; Borsci, G.; Testa, C.; Bonetti, M.; Beltramello, A.; Ghidoni, R.; Benussi, L.; et al. Regional atrophy of transcallosal prefrontal connections in cognitively normal APOE epsilon4 carriers. J. Magn. Reson. Imaging 2009, 29, 1021-1026.
14. Jak, A.J.; Houston, W.S.; Nagel, B.J.; Corey-Bloom, J.; Bondi, M.W. Differential cross-sectional and longitudinal impact of APOE genotype on hippocampal volumes in nondemented older adults. Dement. Geriatr. Cogn. Disord. 2007, 23, 382-389.
15. Chen, K.; Reiman, E.M.; Alexander, G.E.; Caselli, R.J.; Gerkin, R.; Bandy, D.; Domb, A.; Osborne, D.; Fox, N.; Crum, W.R.; et al. Correlations between apolipoprotein E epsilon4 gene dose and whole brain atrophy rates. Am. J. Psychiatry 2007, 164, 916-921.
16. Laitinen, M.H.; Ngandu, T.; Rovio, S.; Helkala, E.L.; Uusitalo, U.; Viitanen, M.; Nissinen, A.; Tuomilehto, J.; Soininen, H.; Kivipelto, M. Fat intake at midlife and risk of dementia and Alzheimer's disease: A population-based study. Dement. Geriatr. Cogn. Disord. 2006, 22, 99-107.
17. Luchsinger, J.A.; Tang, M.X.; Shea, S.; Mayeux, R. Caloric intake and the risk of Alzheimer disease. Arch Neurol. 2002, 59, 1258-1263.
18. Bondi, M.W.; Salmon, D.P.; Galasko, D.; Thomas, R.G.; Thal, L.J. Neuropsychological function and apolipoprotein E genotype in the preclinical detection of Alzheimer's disease. Psychol. Aging 1999, 14, 295-303.
19. Greenwood, P.M.; Lambert, C.; Sunderland, T.; Parasuraman, R. Effects of apolipoprotein E genotype on spatial attention, working memory, and their interaction in healthy, middle-aged adults: Results from the national institute of mental health's biocard study. Neuropsychology 2005, 19, 199-211.
20. Baxter, L.C.; Caselli, R.J.; Johnson, S.C.; Reiman, E.; Osborne, D. Apolipoprotein E epsilon 4 affects new learning in cognitively normal individuals at risk for Alzheimer's disease. Neurobiol. Aging 2003, 24, 947-952.
21. Scarmeas, N.; Habeck, C.G.; Hilton, J.; Anderson, K.E.; Flynn, J.; Park, A.; Stern, Y. APOE related alterations in cerebral activation even at college age. J. Neurol. Neurosurg. Psychiatry 2005, 76, 1440-1444.
22. Greenwood, P.M.; Sunderland, T.; Putnam, K.; Levy, J.; Parasuraman, R. Scaling of visuospatial attention undergoes differential longitudinal change as a function of APOE genotype prior to old age: Results from the NIMH BIOCARD study. Neuropsychology 2005, 19, 830-840.
23. Song, Y.; Stampfer, M.J.; Liu, S. Meta-analysis: Apolipoprotein E genotypes and risk for coronary heart disease. Ann. Intern. Med. 2004, 141, 137-147.
24. Ward, H.; Mitrou, P.N.; Bowman, R.; Luben, R.; Wareham, N.J.; Khaw, K.T.; Bingham, S. APOE genotype, lipids, and coronary heart disease risk: A prospective population study. Arch. Intern. Med. 2009, 169, 1424-1429.
25. Alessandri, J.M.; Guesnet, P.; Vancassel, S.; Astorg, P.; Denis, I.; Langelier, B.; Aid, S.; Poumes-Ballihaut, C.; Champeil-Potokar, G.; Lavialle, M. Polyunsaturated fatty acids in the central nervous system: Evolution of concepts and nutritional implications throughout life. Reprod. Nutr. Dev. 2004, 44, 509-538.
26. Calon, F.; Lim, G.P.; Yang, F.; Morihara, T.; Teter, B.; Ubeda, O.; Rostaing, P.; Triller, A.; Salem, N., Jr.; Ashe, K.H.; et al. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 2004, 43, 633-645.
27. Jump, D.B.; Botolin, D.; Wang, Y.; Xu, J.; Christian, B.; Demeure, O. Fatty acid regulation of hepatic gene transcription. J. Nutr. 2005, 135, 2503-2506.
28. Bouwens, M.; van de Rest, O.; Dellschaft, N.; Bromhaar, M.G.; de Groot, L.C.; Geleijnse, J.M.; Muller, M.; Afman, L.A. Fish-oil supplementation induces antiinflammatory gene expression profiles in human blood mononuclear cells. Am. J. Clin. Nutr. 2009, 90, 415-424.
29. Arterburn, L.M.; Hall, E.B.; Oken, H. Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am. J. Clin. Nutr. 2006, 83, S1467-S1476.
30. Vidgren, H.M.; Agren, J.J.; Schwab, U.; Rissanen, T.; Hanninen, O.; Uusitupa, M.I. Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among healthy young men. Lipids 1997, 32, 697-705.
31. Plourde, M.; Cunnane, S.C. Extremely limited synthesis of long chain polyunsaturates in adults: Implications for their dietary essentiality and use as suppements. Appl. Physiol. Nutr. Metab. 2007, 32, 619-634.
32. Bernoud, N.; Fenart, L.; Benistant, C.; Pageaux, J.F.; Dehouck, M.P.; Moliere, P.; Lagarde, M.; Cecchelli, R.; Lecerf, J. Astrocytes are mainly responsible for the polyunsaturated fatty acid enrichment in blood-brain barrier endothelial cells in vitro. J. Lipid Res. 1998, 39, 1816-1824.
33. Boudrault, C.; Bazinet, R.P.; Ma, D.W. Experimental models and mechanisms underlying the protective effects of n-3 polyunsaturated fatty acids in Alzheimer's disease. J. Nutr. Biochem. 2009, 20, 1-10.
34. Cole, G.M.; Ma, Q.L.; Frautschy, S.A. Dietary fatty acids and the aging brain. Nutr. Rev. 2010, 68, S102-S111.
35. Rocquelin, G.; Guenot, L.; Astorg, P.O.; David, M. Phospholipid content and fatty acid composition of human heart. Lipids 1989, 24, 775-780.
36. Metcalf, R.G.; James, M.J.; Gibson, R.A.; Edwards, J.R.; Stubberfield, J.; Stuklis, R.; Roberts-Thomson, K.; Young, G.D.; Cleland, L.G. Effects of fish-oil supplementation on myocardial fatty acids in humans. Am. J. Clin. Nutr. 2007, 85, 1222-1228.
37. Rocquelin, G.; Guenot, L.; Justrabo, E.; Grynberg, A.; David, M. Fatty acid composition of human heart phospholipids: Data from 53 biopsy specimens. J. Mol. Cell. Cardiol. 1985, 17, 769-773.
38. Barberger-Gateau, P.; Letenneur, L.; Deschamps, V.; Peres, K.; Dartigues, J.F.; Renaud, S. Fish, meat, and risk of dementia: Cohort study. BMJ 2002, 325, 932-933.
39. Barberger-Gateau, P.; Raffaitin, C.; Letenneur, L.; Berr, C.; Tzourio, C.; Dartigues, J.F.; Alperovitch, A. Dietary patterns and risk of dementia: The three-city cohort study. Neurology 2007, 69, 1921-1930.
40. Beydoun, M.A.; Kaufman, J.S.; Sloane, P.D.; Heiss, G.; Ibrahim, J. n-3 Fatty acids, hypertension and risk of cognitive decline among older adults in the atherosclerosis risk in communities (ARIC) study. Public Health Nutr. 2008, 11, 17-29.
41. Eskelinen, M.H.; Ngandu, T.; Helkala, E.L.; Tuomilehto, J.; Nissinen, A.; Soininen, H.; Kivipelto, M. Fat intake at midlife and cognitive impairment later in life: A population-based CAIDE study. Int. J. Geriatr. Psychiatry 2008, 23, 741-747.
42. Huang, T.L.; Zandi, P.P.; Tucker, K.L.; Fitzpatrick, A.L.; Kuller, L.H.; Fried, L.P.; Burke, G.L.; Carlson, M.C. Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4. Neurology 2005, 65, 1409-1414.
43. Kalmijn, S.; Feskens, E.J.; Launer, L.J.; Kromhout, D. Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men. Am. J. Epidemiol. 1997, 145, 33-41.
44. Kalmijn, S.; Launer, L.J.; Ott, A.; Witteman, J.C.; Hofman, A.; Breteler, M.M. Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann. Neurol. 1997, 42, 776-782.
45. Morris, M.C.; Evans, D.A.; Bienias, J.L.; Tangney, C.C.; Bennett, D.A.; Wilson, R.S.; Aggarwal, N.; Schneider, J. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch. Neurol. 2003, 60, 940-946.
46. Morris, M.C.; Evans, D.A.; Tangney, C.C.; Bienias, J.L.; Wilson, R.S. Fish consumption and cognitive decline with age in a large community study. Arch. Neurol. 2005, 62, 1849-1853.
47. Van Gelder, B.M.; Tijhuis, M.; Kalmijn, S.; Kromhout, D. Fish consumption, n-3 fatty acids, and subsequent 5-y cognitive decline in elderly men: The Zutphen elderly study. Am. J. Clin. Nutr. 2007, 85, 1142-1147.
48. Vercambre, M.N.; Boutron-Ruault, M.C.; Ritchie, K.; Clavel-Chapelon, F.; Berr, C. Long-term association of food and nutrient intakes with cognitive and functional decline: A 13-year follow-up study of elderly French women. Br. J. Nutr. 2009, 102, 419-427.
49. Whalley, L.J.; Fox, H.C.; Wahle, K.W.; Starr, J.M.; Deary, I.J. Cognitive aging, childhood intelligence, and the use of food supplements: Possible involvement of n-3 fatty acids. Am. J. Clin. Nutr. 2004, 80, 1650-1657.
50. Beydoun, M.A.; Kaufman, J.S.; Satia, J.A.; Rosamond, W.; Folsom, A.R. Plasma n-3 fatty acids and the risk of cognitive decline in older adults: The atherosclerosis risk in communities study. Am. J. Clin. Nutr. 2007, 85, 1103-1111.
51. Dullemeijer, C.; Durga, J.; Brouwer, I.A.; van de Rest, O.; Kok, F.J.; Brummer, R.J.; van Boxtel, M.P.; Verhoef, P. n-3 Fatty acid proportions in plasma and cognitive performance in older adults. Am. J. Clin. Nutr. 2007, 86, 1479-1485.
52. Heude, B.; Ducimetiere, P.; Berr, C. Cognitive decline and fatty acid composition of erythrocyte membranes-The EVA study. Am. J. Clin. Nutr. 2003, 77, 803-808.
53. Samieri, C.; Feart, C.; Letenneur, L.; Dartigues, J.F.; Peres, K.; Auriacombe, S.; Peuchant, E.; Delcourt, C.; Barberger-Gateau, P. Low plasma eicosapentaenoic acid and depressive symptomatology are independent predictors of dementia risk. Am. J. Clin. Nutr. 2008, 88, 714-721.
54. Schaefer, E.J.; Bongard, V.; Beiser, A.S.; Lamon-Fava, S.; Robins, S.J.; Au, R.; Tucker, K.L.; Kyle, D.J.; Wilson, P.W.; Wolf, P.A. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: The Framingham Heart Study. Arch. Neurol. 2006, 63, 1545-1550.
55. Mapstone, M.; Cheema, A.K.; Fiandaca, M.S.; Zhong, X.; Mhyre, T.R.; MacArthur, L.H.; Hall, W.J.; Fisher, S.G.; Peterson, D.R.; Haley, J.M.; et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat. Med. 2014, 20, 415-418.
56. Ng, T.P.; Gao, Q.; Niti, M.; Feng, L.; Yap, K.B. Omega-3 polyunsaturated fatty acid supplements and cognitive decline: Singapore Longitudinal Aging Studies. J. Nutr. Health Aging 2011, 15, 32-35.
57. Kritz-Silverstein, D.; Lopez, L.B.; Barrett Connor, E. High dietary and plasma levels of the omega-3 fatty acid docosahexaenoic acid are associated with decreased dementia risk: The Rancho Bernardo study. J. Nutr. Health Aging 2011, 15, 25-31.
58. Quinn, J.F.; Raman, R.; Thomas, R.G.; Yurko-Mauro, K.; Nelson, E.B.; Van Dyck, C.; Galvin, J.E.; Emond, J.; Jack, C.R., Jr.; Weiner, M.; et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: A randomized trial. JAMA 2010, 304, 1903-1911.
59. Whalley, L.J.; Deary, I.J.; Starr, J.M.; Wahle, K.W.; Rance, K.A.; Bourne, V.J.; Fox, H.C. n-3 Fatty acid erythrocyte membrane content, APOE varepsilon4, and cognitive variation: An observational follow-up study in late adulthood. Am. J. Clin. Nutr. 2008, 87, 449-454.
60. Stuyt, P.M.; Brenninkmeijer, B.J.; Demacker, P.N.; Hendriks, J.C.; van Elteren, P.; Stalenhoef, A.F.; van't Laar, A. Apolipoprotein E phenotypes, serum lipoproteins and apolipoproteins in angiographically assessed coronary heart disease. Scand. J. Clin. Lab. Investig. 1991, 51, 425-435.
61. Salazar, L.A.; Hirata, M.H.; Giannini, S.D.; Forti, N.; Diament, J.; Lima, T.M.; Hirata, R.D. Seven DNA polymorphisms at the candidate genes of atherosclerosis in Brazilian women with angiographically documented coronary artery disease. Clin. Chim. Acta 2000, 300, 139-149.
62. Haan, M.N.; Mayeda, E.R. Apolipoprotein E genotype and cardiovascular diseases in the elderly. Curr. Cardiovasc. Risk Rep. 2010, 4, 361-368.
63. Khan, T.A.; Shah, T.; Prieto, D.; Zhang, W.; Price, J.; Fowkes, G.R.; Cooper, J.; Talmud, P.J.; Humphries, S.E.; Sundstrom, J.; et al. Apolipoprotein E genotype, cardiovascular biomarkers and risk of stroke: Systematic review and meta-analysis of 14,015 stroke cases and pooled analysis of primary biomarker data from up to 60,883 individuals. Int. J. Epidemiol. 2013, 42, 475-492.
64. Djousse, L.; Akinkuolie, A.O.; Wu, J.H.; Ding, E.L.; Gaziano, J.M. Fish consumption, omega-3 fatty acids and risk of heart failure: A meta-analysis. Clin. Nutr. 2012, 31, 846-853.
65. Siscovick, D.S.; Raghunathan, T.E.; King, I.; Weinmann, S.; Wicklund, K.G.; Albright, J.; Bovbjerg, V.; Arbogast, P.; Smith, H.; Kushi, L.H.; et al. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA 1995, 274, 1363-1367.
66. Tavani, A.; Pelucchi, C.; Negri, E.; Bertuzzi, M.; la Vecchia, C. n-3 Polyunsaturated fatty acids, fish, and nonfatal acute myocardial infarction. Circulation 2001, 104, 2269-2272.
67. Albert, C.M.; Hennekens, C.H.; O'Donnell, C.J.; Ajani, U.A.; Carey, V.J.; Willett, W.C.; Ruskin, J.N.; Manson, J.E. Fish consumption and risk of sudden cardiac death. JAMA 1998, 279, 23-28.
68. Hennebelle, M.; Plourde, M.; Chouinard-Watkins, R.; Castellano, C.A.; Barberger-Gateau, P.; Cunnane, S.C. Ageing and APOE change DHA homeostasis: Relevance to age-related cognitive decline. Proc. Nutr. Soc. 2014, 73, 80-86.
69. Fortier, M.; Tremblay-Mercier, J.; Plourde, M.; Chouinard-Watkins, R.; Vandal, M.; Pifferi, F.; Freemantle, E.; Cunnane, S.C. Higher plasma n-3 fatty acid status in the moderately healthy elderly in southern Quebec: Higher fish intake or aging-related change in n-3 fatty acid metabolism? Prostaglandins Leukot. Essent. Fatty Acids 2010, 82, 277-280.
70. Carvalho-Wells, A.L.; Jackson, K.G.; Gill, R.; Olano-Martin, E.; Lovegrove, J.A.; Williams, C.M.; Minihane, A.M. Interactions between age and APOE genotype on fasting and postprandial triglycerides levels. Atherosclerosis 2010, 212, 481-487.
71. Liang, S.; Steffen, L.M.; Steffen, B.T.; Guan, W.; Weir, N.L.; Rich, S.S.; Manichaikul, A.; Vargas, J.D.; Tsai, M.Y. APOE genotype modifies the association between plasma omega-3 fatty acids and plasma lipids in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2013, 228, 181-187.
72. Chiu, C.C.; Su, K.P.; Cheng, T.C.; Liu, H.C.; Chang, C.J.; Dewey, M.E.; Stewart, R.; Huang, S.Y. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: A preliminary randomized double-blind placebo-controlled study. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32, 1538-1544.
73. Freund-Levi, Y.; Eriksdotter-Jonhagen, M.; Cederholm, T.; Basun, H.; Faxen-Irving, G.; Garlind, A.; Vedin, I.; Vessby, B.; Wahlund, L.O.; Palmblad, J. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: A randomized double-blind trial. Arch. Neurol. 2006, 63, 1402-1408.
74. Kotani, S.; Sakaguchi, E.; Warashina, S.; Matsukawa, N.; Ishikura, Y.; Kiso, Y.; Sakakibara, M.; Yoshimoto, T.; Guo, J.; Yamashima, T. Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci. Res. 2006, 56, 159-164.
75. Suzuki, H.; Morikawa, Y.; Takahashi, H. Effect of DHA oil supplementation on intelligence and visual acuity in the elderly. World Rev. Nutr. Diet. 2001, 88, 68-71.
76. Terano, T.; Fujishiro, S.; Ban, T.; Yamamoto, K.; Tanaka, T.; Noguchi, Y.; Tamura, Y.; Yazawa, K.; Hirayama, T. Docosahexaenoic acid supplementation improves the moderately severe dementia from thrombotic cerebrovascular diseases. Lipids 1999, 34, S345-S346.
77. Scheltens, P.; Kamphuis, P.J.; Verhey, F.R.; Olde Rikkert, M.G.; Wurtman, R.J.; Wilkinson, D.; Twisk, J.W.; Kurz, A. Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial. Alzheimers Dement. 2010, 6, 1-10.
78. Yurko-Mauro, K.; McCarthy, D.; Rom, D.; Nelson, E.B.; Ryan, A.S.; Blackwell, A.; Salem, N., Jr.; Stedman, M. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement. 2010, 6, 456-464.
79. Samieri, C.; Feart, C.; Proust-Lima, C.; Peuchant, E.; Dartigues, J.F.; Amieva, H.; Barberger-Gateau, P. Omega-3 fatty acids and cognitive decline: Modulation by apoeepsilon4 allele and depression. Neurobiol. Aging 2011, 32, e2313-e2322.
80. Van de Rest, O.; Geleijnse, J.M.; Kok, F.J.; van Staveren, W.A.; Dullemeijer, C.; Olderikkert, M.G.; Beekman, A.T.; de Groot, C.P. Effect of fish oil on cognitive performance in older subjects: A randomized, controlled trial. Neurology 2008, 71, 430-438.
81. Albert, C.M.; Campos, H.; Stampfer, M.J.; Ridker, P.M.; Manson, J.E.; Willett, W.C.; Ma, J. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N. Engl. J. Med. 2002, 346, 1113-1118.
82. Calder, P.C.; Yaqoob, P. Marine omega-3 fatty acids and coronary heart disease. Curr. Opin. Cardiol. 2012, 27, 412-419.
83. Kromhout, D.; Yasuda, S.; Geleijnse, J.M.; Shimokawa, H. Fish oil and omega-3 fatty acids in cardiovascular disease: Do they really work? Eur. Heart J. 2012, 33, 436-443.
84. Oikawa, S.; Yokoyama, M.; Origasa, H.; Matsuzaki, M.; Matsuzawa, Y.; Saito, Y.; Ishikawa, Y.; Sasaki, J.; Hishida, H.; Itakura, H.; et al. Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: Sub-analysis of the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 2009, 206, 535-539.
85. Yokoyama, M.; Origasa, H.; Matsuzaki, M.; Matsuzawa, Y.; Saito, Y.; Ishikawa, Y.; Oikawa, S.; Sasaki, J.; Hishida, H.; Itakura, H.; et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis. Lancet 2007, 369, 1090-1098.
86. GISSI-Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico). Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial. Lancet 1999, 354, 447-455.
87. Gissi, H.F.I.; Tavazzi, L.; Maggioni, A.P.; Marchioli, R.; Barlera, S.; Franzosi, M.G.; Latini, R.; Lucci, D.; Nicolosi, G.L.; Porcu, M.; et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet 2008, 372, 1223-1230.
88. Casula, M.; Soranna, D.; Catapano, A.L.; Corrao, G. Long-term effect of high dose omega-3 fatty acid supplementation for secondary prevention of cardiovascular outcomes: A meta-analysis of randomized, placebo controlled trials [corrected]. Atheroscler. Suppl. 2013, 14, 243-251.
89. Kromhout, D.; Giltay, E.J.; Geleijnse, J.M.; Alpha Omega Trial Group. n-3 Fatty acids and cardiovascular events after myocardial infarction. N. Engl. J. Med. 2010, 363, 2015-2026.
90. Galan, P.; Kesse-Guyot, E.; Czernichow, S.; Briancon, S.; Blacher, J.; Hercberg, S.; SU.FOL.OM3 Collaborative Group. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: A randomised placebo controlled trial. BMJ 2010, 341, c6273, doi:10.1136/bmj.c6273.
91. Rauch, B.; Schiele, R.; Schneider, S.; Diller, F.; Victor, N.; Gohlke, H.; Gottwik, M.; Steinbeck, G.; del Castillo, U.; Sack, R.; et al. Omega, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 2010, 122, 2152-2159.
92. Carvalho-Wells, A.L.; Jackson, K.G.; Lockyer, S.; Lovegrove, J.A.; Minihane, A.M. APOE genotype influences triglyceride and C-reactive protein responses to altered dietary fat intake in UK adults. Am. J. Clin. Nutr. 2012, 96, 1447-1453.
93. Minihane, A.M.; Khan, S.; Leigh-Firbank, E.C.; Talmud, P.; Wright, J.W.; Murphy, M.C.; Griffin, B.A.; Williams, C.M. APOE polymorphism and fish oil supplementation in subjects with an atherogenic lipoprotein phenotype. Arterioscler. Thromb. Vasc. Biol. 2000, 20, 1990-1997.
94. Olano-Martin, E.; Anil, E.; Caslake, M.J.; Packard, C.J.; Bedford, D.; Stewart, G.; Peiris, D.; Williams, C.M.; Minihane, A.M. Contribution of apolipoprotein E genotype and docosahexaenoic acid to the LDL-cholesterol response to fish oil. Atherosclerosis 2010, 209, 104-110.
95. Plourde, M.; Vohl, M.C.; Vandal, M.; Couture, P.; Lemieux, S.; Cunnane, S.C. Plasma n-3 fatty acid response to an n-3 fatty acid supplement is modulated by APOE epsilon4 but not by the common PPAR-alpha L162V polymorphism in men. Br. J. Nutr. 2009, 102, 1121-1124.
96. 13C-labelled DHA metabolism in elderly human subjects carrying the APOE epsilon4 allele. Br. J. Nutr. 2013, 110, 1751-1759.
97. 13C-DHA before and during fish-oil supplementation in healthy older individuals. Am. J. Clin. Nutr. 2014, 100, 105-112.
98. Conway, V.; Allard, M.J.; Minihane, A.M.; Jackson, K.G.; Lovegrove, J.A.; Plourde, M. Postprandial enrichment of triacylglycerol-rich lipoproteins with omega-3 fatty acids: Lack of an interaction with apolipoprotein E genotype? Lipids Health Dis. 2014, 13, 148, doi:10.1186/1476-511X-13-148.
99. Dang, T.M.; Conway, V.; Plourde, M. Disrupt Fatty Acid Distribution in HDL and LDL According to Apolipoprotein E Genotype. In Proceedings of the 7th Congress of the International Society of Nutrigenetics/Nutrigenomics (ISNN), Quebec City, QC, Canada, 6-8 October 2013; Volume 6, pp. 199-253.
100. Gregg, R.E.; Zech, L.A.; Schaefer, E.J.; Stark, D.; Wilson, D.; Brewer, H.B., Jr. Abnormal in vivo metabolism of apolipoprotein E4 in humans. J. Clin. Investig. 1986, 78, 815-821.
101. Weisgraber, K.H. Apolipoprotein E: Structure-function relationships. Adv. Protein Chem. 1994, 45, 249-302.
102. Bour, A.; Grootendorst, J.; Vogel, E.; Kelche, C.; Dodart, J.C.; Bales, K.; Moreau, P.H.; Sullivan, P.M.; Mathis, C. Middle-aged human APOE4 targeted-replacement mice show retention deficits on a wide range of spatial memory tasks. Behav. Brain Res. 2008, 193, 174-182.
103. Siegel, J.A.; Haley, G.E.; Raber, J. Apolipoprotein E isoform-dependent effects on anxiety and cognition in female TR mice. Neurobiol. Aging 2010, 33, 345-358.
104. Bourre, J.M. Roles of unsaturated fatty acids (especially omega-3 fatty acids) in the brain at various ages and during ageing. J. Nutr. Health Aging 2004, 8, 163-174.
105. Klein, R.C.; Mace, B.E.; Moore, S.D.; Sullivan, P.M. Progressive loss of synaptic integrity in human apolipoprotein E4 targeted replacement mice and attenuation by apolipoprotein E2. Neuroscience 2010, 171, 1265-1272.
106. Nishitsuji, K.; Hosono, T.; Nakamura, T.; Bu, G.; Michikawa, M. Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an in vitro blood-brain barrier model. J. Biol. Chem. 2011, 286, 17536-17542.
107. Liu, Q.; Trotter, J.; Zhang, J.; Peters, M.M.; Cheng, H.; Bao, J.; Han, X.; Weeber, E.J.; Bu, G. Neuronal LRP1 knockout in adult mice leads to impaired brain lipid metabolism and progressive, age-dependent synapse loss and neurodegeneration. J. Neurosci. 2010, 30, 17068-17078.
108. Bu, G. Apolipoprotein E and its receptors in Alzheimer's disease: Pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 2009, 10, 333-344.
109. Mahley, R.W.; Weisgraber, K.H.; Huang, Y. Apolipoprotein E: Structure determines function, from atherosclerosis to Alzheimer's disease to aids. J. Lipid Res. 2009, 50, S183-S188.
110. Dagenais, C.; Rousselle, C.; Pollack, G.M.; Scherrmann, J.M. Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice. J. Cereb. Blood Flow Metab. 2000, 20, 381-386.
111. Ouellet, M.; Emond, V.; Chen, C.T.; Julien, C.; Bourasset, F.; Oddo, S.; LaFerla, F.; Bazinet, R.P.; Calon, F. Diffusion of docosahexaenoic and eicosapentaenoic acids through the blood-brain barrier: An in situ cerebral perfusion study. Neurochem. Int. 2009, 55, 476-482.
112. Vandal, M.; Alata, W.; Tremblay, C.; Rioux-Perreault, C.; Salem, N., Jr.; Calon, F.; Plourde, M. Reduction in DHA transport to the brain of mice expressing human APOE4 compared to APOE2. J. Neurochem. 2014, 129, 516-526.
113. Poirier, J. Apolipoprotein E represents a potent gene-based therapeutic target for the treatment of sporadic Alzheimer's disease. Alzheimers Dement. 2008, 4, S91-S97.
114. Conway, V.; Larouche, A.; Alata, W.; Vandal, M.; Calon, F.; Plourde, M. Apolipoprotein E isoforms disrupt long-chain fatty acid distribution in the plasma, the liver and the adipose tissue of mice. Prostaglandins Leukot. Essent. Fatty Acids 2014, in Press.
115. Ravona-Springer, R.; Davidson, M.; Noy, S. Is the distinction between Alzheimer's disease and vascular dementia possible and relevant? Dialogues Clin. Neurosci. 2003, 5, 7-15.
116. Roher, A.E.; Debbins, J.P.; Malek-Ahmadi, M.; Chen, K.; Pipe, J.G.; Maze, S.; Belden, C.; Maarouf, C.L.; Thiyyagura, P.; Mo, H.; et al. Cerebral blood flow in Alzheimer's disease. Vasc. Health Risk Manag. 2012, 8, 599-611.
117. Kalaria, R.N.; Ballard, C. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis. Assoc. Disord. 1999, 13, S115-S123.
118. Norton, S.; Matthews, F.E.; Barnes, D.E.; Yaffe, K.; Brayne, C. Potential for primary prevention of Alzheimer's disease: An analysis of population-based data. Lancet Neurol. 2014, 13, 788-794.
119. Kivipelto, M.; Helkala, E.L.; Laakso, M.P.; Hanninen, T.; Hallikainen, M.; Alhainen, K.; Soininen, H.; Tuomilehto, J.; Nissinen, A. Midlife vascular risk factors and Alzheimer's disease in later life: Longitudinal, population based study. BMJ 2001, 322, 1447-1451.
120. Notkola, I.L.; Sulkava, R.; Pekkanen, J.; Erkinjuntti, T.; Ehnholm, C.; Kivinen, P.; Tuomilehto, J.; Nissinen, A. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 1998, 17, 14-20.
121. Bell, R.D.; Winkler, E.A.; Singh, I.; Sagare, A.P.; Deane, R.; Wu, Z.; Holtzman, D.M.; Betsholtz, C.; Armulik, A.; Sallstrom, J.; et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 2012, 485, 512-516.
122. Halliday, M.R.; Pomara, N.; Sagare, A.P.; Mack, W.J.; Frangione, B.; Zlokovic, B.V. Relationship between cyclophilin A levels and matrix metalloproteinase 9 activity in cerebrospinal fluid of cognitively normal apolipoprotein E4 carriers and blood-brain barrier breakdown. JAMA Neurol. 2013, 70, 1198-1200.
123. Vandal, M.; Freemantle, E.; Tremblay-Mercier, J.; Plourde, M.; Fortier, M.; Bruneau, J.; Gagnon, J.; Begin, M.; Cunnane, S.C. Plasma omega-3 fatty acid response to a fish oil supplement in the healthy elderly. Lipids 2008, 43, 1085-1089.
124. Plourde, M.; Tremblay-Mercier, J.; Fortier, M.; Pifferi, F.; Cunnane, S.C. Eicosapentaenoic acid decreases postprandial beta-hydroxybutyrate and free fatty acid responses in healthy young and elderly. Nutrition 2009, 25, 289-294.
125. Fanelli, F.; Sepe, S.; D'Amelio, M.; Bernardi, C.; Cristiano, L.; Cimini, A.; Cecconi, F.; Ceru, M.P.; Moreno, S. Age-dependent roles of peroxisomes in the hippocampus of a transgenic mouse model of Alzheimer's disease. Mol. Neurodegener. 2013, 8, 8, doi:10.1186/1750-1326-8-8.
126. Shi, R.; Zhang, Y.; Shi, Y.; Shi, S.; Jiang, L. Inhibition of peroxisomal β-oxidation by thioridazine increases the amount of VLCFAs and Aβ generation in the rat brain. Neurosci. Lett. 2012, 528, 6-10.
127. Astarita, G.; Jung, K.M.; Berchtold, N.C.; Nguyen, V.Q.; Gillen, D.L.; Head, E.; Cotman, C.W.; Piomelli, D. Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer's disease. PLoS One 2010, 5, e12538, doi:10.1371/journal.pone.0012538.
128. Lizard, G.; Rouaud, O.; Demarquoy, J.; Cherkaoui-Malki, M.; Iuliano, L. Potential roles of peroxisomes in Alzheimer's disease and in dementia of the Alzheimer's type. J. Alzheimer's Dis. 2012, 29, 241-254.
129. Guzzardi, M.A.; Iozzo, P. Fatty heart, cardiac damage, and inflammation. Rev. Diabet. Stud. 2011, 8, 403-417.
130. Martin, M.A.; Gomez, M.A.; Guillen, F.; Bornstein, B.; Campos, Y.; Rubio, J.C.; de la Calzada, C.S.; Arenas, J. Myocardial carnitine and carnitine palmitoyltransferase deficiencies in patients with severe heart failure. Biochim. Biophys. Acta 2000, 1502, 330-336.
131. Ben-Zvi, A.; Lacoste, B.; Kur, E.; Andreone, B.J.; Mayshar, Y.; Yan, H.; Gu, C. Mfsd2a is critical for the formation and function of the blood-brain barrier. Nature 2014, 509, 507-511.
132. Nguyen, L.N.; Ma, D.; Shui, G.; Wong, P.; Cazenave-Gassiot, A.; Zhang, X.; Wenk, M.R.; Goh, E.L.; Silver, D.L. Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid. Nature 2014, 509, 503-506.
133. Zhao, Z.; Zlokovic, B.V. Blood-brain barrier: A dual life of Mfsd2a? Neuron 2014, 82, 728-730.
134. Betsholtz, C. Physiology: Double function at the blood-brain barrier. Nature 2014, 509, 432-433.